The company ten23 health has opened a new, cutting-edge facility in the town in Haut-Valais. Called VIVA2, it is the tangible result of an ambitious project announced in June 2022. This new, cutting-edge infrastructure will strengthen significantly the region’s capacity for producing sterile medicines.
The opening represents a major step forward for the pharmaceutical industry in Valais, combining technological innovation and sustainability. The new facility has been designed to respond to the increasing challenges in the sector, while consolidating Valais’ position as a centre of excellence for the life sciences.
A facility at the cutting edge of technology
VIVA2 is a new-generation pharmaceutical facility, with ultra-modern equipment. Its latest-generation aseptic filling system, combined with rigorous quality controls, guarantees the production of high-precision medicines. It can manufacture over 30 million units a year, in syringes, cartridges or bottles. The factory can adapt to different kinds of containers and respond to the changing needs of the pharmaceutical industry.
The building’s façade is fitted with photovoltaic panels, which generate a significant portion of the energy needed to run it. This environmentally responsible approach is part of the company’s long-term vision.
A major asset for Valais and the life sciences
The new factory marks an important step for the development of the pharmaceutical industry in the canton. As well as creating new jobs, it is strengthening the region’s position as a centre of innovation in the life sciences field, potentially attracting new investments and new talent.
It also attests to the dynamism of the local biopharmaceutical sector and opens up new prospects for research, development and the production of innovative medicines in the region.
The new development positions Valais as a key actor on the international life sciences stage.
Source : press release